The 7 nm core/3 nm shell NPs show good magnetic and photoluminesc

The 7 nm core/3 nm shell NPs show good magnetic and photoluminescence (PL) responses. The observed PL emission/excitation spectra are shifted to shorter wavelengths, compared to a reference ZnSe NP sample. A dramatic reduction of PL quantum yield is also observed. The temperature dependence of the magnetization for the core/shell NPs shows the characteristic features of two coexisting and interacting magnetic (Fe3O4) and nonmagnetic (ZnSe) phases. Compared to a reference Fe3O4 NP sample, the room-temperature

Neel relaxation time in core/shell NPs is three times longer. EPZ5676 mouse (C) 2011 American Institute of Physics. [doi:10.1063/1.3565190]“
“Low paraoxonase-1 (PON1) activity has been regarded as one of risk factors for cardiovascular disease. We showed that low PON1 activity was independently

associated with carotid intima-media thickness (IMT) and heart to femoral pulse wave velocity (hfPWV) in hypertensive patients. Our results indicate that PON1 activity may reflect early structural and functional changes of arteries in this population.”
“BACKGROUND: Donation after cardiac death (DCD) to overcome the donor organ shortage is now moving into the clinical setting, but the medium-term outcome after DCD lung transplantation (LTx) remains largely unknown.

METHODS: In this retrospective Crenolanib datasheet study, DCD LTx recipients (n = 21) were compared with a cohort of donation-after-brain-death (DBD) LTx recipients (n = 154) transplanted between February 2007 and July 2010. Immediate (post)operative outcome was evaluated by assessing need for pen-operative extracorporeal membrane oxygenation (ECMO), time to extubation, hospital discharge and primary graft dysfunction (PGD) within the first 48 hours. Survival, incidence of bronchiolitis obliterans syndrome (BOS), selleck inhibitor acute rejection (AR) and inflammatory markers in blood and in bronchoalveolar lavage (BAL) were assessed and compared over a median follow-up of

327 days for DCD and 531 days for DBD, showing no statistically significant difference (NS).

RESULTS: There were no differences between groups with regard to patient characteristics except for a higher number of patients transplanted for obliterative bronchiolitis in the DCD group (4 of 21 vs 7 of 154; p < 0.05). In the DCD group, 2 of 21 patients died, vs 23 of 154 patients in the DBD group (NS). Actuarial survival rates at 6 months, 1 year and 3 years are 95%, 95% and 71% for the DCD group and 96%, 91% and 75% for the DBD group (NS). Three patients (14%) in the DCD group developed BOS vs 15 patients (10%) in the DBD group (NS). Survival and freedom from BOS were not different between the groups. AR, inflammatory markers and immediate (post)operative outcome also did not differ.

CONCLUSIONS: In our experience, both early- and medium-term outcome in DCD lung recipients is comparable to that of DBD lung recipients.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>